Link to: Introducing Citidaron
Introducing CITIDARON®
Link to: How Citidaron works
How CITIDARON® works
Link to: When to use CITIDARON
When to use CITIDARON®?
Link to: Why use CITIDARON
Why use CITIDARON®?
Link to: How to use CITIDARON
How to use CITIDARON®?
Link to: CITIDARON prescribing considerations
CITIDARON® prescribing considerations
HOW CITIDARON® WORKS
- CITIDARON® is a partial agonist of the α4β2 nicotinic acetylcholine receptor 1
- CITIDARON® competes with nicotine for the same receptors and gradually displaces nicotine due to its stronger binding. It has lower ability to stimulate nicotinic receptors 1
- It prevents nicotine-dependent full activation of the mesolimbic dopamine system and moderately increases level of dopamine in the brain. This alleviates the central symptoms of nicotine withdrawal 1
- In the peripheral nervous system, it influences breathing, catecholamine secretion, and blood pressure and helps mitigate peripheral symptoms of nicotine withdrawal 1
Adverse Events / Product Complaints or for
Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760
Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760
Healthcare professionals are asked to report any suspected adverse reactions. To report an adverse event or a product complaint about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or 012057766. Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting form and information can be found at http://www.hpra.ie then click on “report an issue”.
IE-CH-1560 Date of Preparation April 2024